Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19862469 | 0.97 | ALDH1A1 (0.54) | ALDH1A1MAPK1L3MBTL1ALOX5TDP1 | |
| SCHEMBL19862466 | 0.92 | ALOX5 (0.51) | ALDH1A1MAPK1L3MBTL1ALOX5TDP1 | |
| SCHEMBL19862468 | 0.92 | ALOX5 (0.51) | ALDH1A1MAPK1L3MBTL1ALOX5TDP1 | |
| SCHEMBL31187902 | 0.91 | HTT (0.52) | ALDH1A1MAPK1L3MBTL1ALOX5TDP1 | |
| SCHEMBL8886811 | 0.91 | ALOX5 (0.52) | ALDH1A1MAPK1L3MBTL1ALOX5SLC6A2 | |
| SCHEMBL24187637 | 0.89 | LMNA (0.49) | ALDH1A1MAPK1L3MBTL1ALOX5TDP1 | |
| SCHEMBL20510397 | 0.88 | CA1 (0.55) | ALDH1A1MAPK1L3MBTL1ALOX5TDP1 | |
| SCHEMBL25259191 | 0.88 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1ALOX5TDP1 | |
| SCHEMBL18673 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 | |
| SCHEMBL3963428 | 0.87 | ALDH1A1 (0.68) | ALDH1A1MAPK1L3MBTL1TDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044280-A1 | Y-TYPE DISCRETE POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREOF | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044280-A1 | Y-TYPE DISCRETE POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREOF | IDUA, YWHAZ, DDOST | ALDH1A1 3213/4885MAPK1 2055/4885L3MBTL1 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.